$151,22
-$1,62(-1,05%)
*Data last updated: 2026-04-08 00:43 (UTC+8)
As of 2026-04-08 00:43, NOVARTIS AG-SPONSORED ADR (NVS) is priced at $151,22, with a total market cap of $291,89B, a P/E ratio of 19,01, and a dividend yield of 2,00%. Today, the stock price fluctuated between $149,48 and $151,49. The current price is 1,16% above the day's low and 0,17% below the day's high, with a trading volume of 1,93M. Over the past 52 weeks, NVS has traded between $149,48 to $154,03, and the current price is -1,82% away from the 52-week high.
NVS Key Stats
Yesterday's Close$152,84
Market Cap$291,89B
Volume1,93M
P/E Ratio19,01
Dividend Yield (TTM)2,00%
Dividend Amount$3,08
Diluted EPS (TTM)7,32
Net Income (FY)$14,05B
Revenue (FY)$54,81B
Earnings Date2026-05-05
EPS Estimate2,13
Revenue Estimate$13,54B
Shares Outstanding1,90B
Beta (1Y)0.522
Ex-Dividend Date2026-03-11
Dividend Payment Date2026-03-16
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOVasant Narasimhan
HeadquartersBasel,None,CH
Official Websitehttps://www.novartis.com
NOVARTIS AG-SPONSORED ADR (NVS) FAQ
What's the stock price of NOVARTIS AG-SPONSORED ADR (NVS) today?
x
NOVARTIS AG-SPONSORED ADR (NVS) is currently trading at $151,22, with a 24h change of -1,05%. The 52-week trading range is $149,48–$154,03.
What are the 52-week high and low prices for NOVARTIS AG-SPONSORED ADR (NVS)?
x
What is the price-to-earnings (P/E) ratio of NOVARTIS AG-SPONSORED ADR (NVS)? What does it indicate?
x
What is the market cap of NOVARTIS AG-SPONSORED ADR (NVS)?
x
What is the most recent quarterly earnings per share (EPS) for NOVARTIS AG-SPONSORED ADR (NVS)?
x
Should you buy or sell NOVARTIS AG-SPONSORED ADR (NVS) now?
x
What factors can affect the stock price of NOVARTIS AG-SPONSORED ADR (NVS)?
x
How to buy NOVARTIS AG-SPONSORED ADR (NVS) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
